| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 06/15/2011 | EP1213971B1 Improving condition of elderly pets |
| 06/15/2011 | EP0939804B2 NEUTROKINE alpha |
| 06/15/2011 | CN1969874B Externally applied pharmaceutical composition of abafungin |
| 06/15/2011 | CN1832948B 1- alkyl-1-azoniabicyclo (2.2.2) octane carbamate derivatives and their use as muscarinic receptor antagonists |
| 06/15/2011 | CN1820734B Treatment with anti-erbb2 antibodies |
| 06/15/2011 | CN102099039A Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis |
| 06/15/2011 | CN102099027A Fulvic acid and antibiotic combination |
| 06/15/2011 | CN102099026A Therapeutic compositions containing macitentan |
| 06/15/2011 | CN102093489A Amphiphilic N-long chain alkyl-N-arginine chitosan derivative and preparation of derivative micelle |
| 06/15/2011 | CN102091330A Pharmaceutical compositions comprising valsartan and NEP inhibitors |
| 06/15/2011 | CN102091134A Traditional Chinese medicinal composition for resisting multi-medicine tolerance of antibiotics |
| 06/15/2011 | CN102091036A Compound liposome containing anti-tumor drugs and preparation method and application thereof |
| 06/15/2011 | CN101708159B Preparation method for heat-sensitive medicament suspension |
| 06/15/2011 | CN101522194B Prophylactic/therapeutic agent for renal dysfunction |
| 06/15/2011 | CN101381366B Benzimidazole derivative and its use as a ii receptor antagonist |
| 06/15/2011 | CN101176788B Pharmaceutical composition for ACE restrainer/uretica/folic acid, and uses thereof |
| 06/15/2011 | CN101119718B Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics |
| 06/15/2011 | CN101094847B Aryloxy-substituted benzimidazole derivatives |
| 06/15/2011 | CN101056855B Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient |
| 06/14/2011 | US7960570 Small molecule inhibitors of rotamase enzyme activity |
| 06/14/2011 | US7960437 Improving aesthetic appearance of skin by reducing wrinkles and fine lines, improving smoothness, texture, firmness, moisture, elasticity and resilience; topical application of a mixture of a phtyol and a cyclic-AMP derivative |
| 06/14/2011 | US7960433 Treatment of chemokine mediated diseases |
| 06/14/2011 | US7960367 Pregnane steroids and their use in the treatment of CNS disorders |
| 06/14/2011 | US7960366 Substituted tetracycline compounds as synergistic antifungal agents |
| 06/14/2011 | US7960362 Synthetic agonists of TLR9 |
| 06/14/2011 | US7960358 Antisense modulation of stearoyl-CoA desaturase expression |
| 06/14/2011 | US7960356 Induces production of a cytokine or activates dendritic cells, natural killer cells and monocytes; autoimmune disorders; vaccine |
| 06/14/2011 | US7960341 Methods and compositions for treating polycystic ovary syndrome |
| 06/14/2011 | US7960163 Matriptase, a serine protease and its applications |
| 06/14/2011 | US7960128 TRP8, a transient receptor potential channel expressed in taste receptor cells |
| 06/14/2011 | US7960127 Using channel protein to identify inhibitors of bitter and/or sweet taste preception |
| 06/14/2011 | US7959946 Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| 06/14/2011 | US7959934 Method for rapid generation of mature dendritic cells |
| 06/14/2011 | US7959930 Rescue of influenza virus |
| 06/14/2011 | US7959929 isolated influenza virus that is capable of infecting a canid animal; genetic engineered influenza virus; vaccines for inducing an immune response against an influenza virus; veterinary medicine |
| 06/14/2011 | US7959907 Method of treating cancer by combination therapy using TNF and alpha-galactosylceramide |
| 06/14/2011 | CA2520586C Novel ido inhibitors and methods of use |
| 06/14/2011 | CA2503183C Salmeterol superfine formulation |
| 06/14/2011 | CA2494962C Tyrosine kinase inhibitors |
| 06/14/2011 | CA2494241C Botulinum toxin pharmaceutical compositions |
| 06/14/2011 | CA2476127C New pharmaceutical compositions based on anticholinergics and egfr kinase inhibitors |
| 06/14/2011 | CA2452752C Dye-azide compounds for dual phototherapy |
| 06/14/2011 | CA2445322C Use of the abc expression promoting agent pioglitazone for the treatment of arteriosclerosis obliterans |
| 06/14/2011 | CA2443325C Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators |
| 06/14/2011 | CA2426292C Net, a transcription factor of the tcf family, as regulator of angiogenic factor expression |
| 06/14/2011 | CA2413313C Antitumor effect potentiators |
| 06/14/2011 | CA2399482C Method for classifying and treating physiologic brain imbalances using quantitative eeg |
| 06/14/2011 | CA2338419C Pulmonary delivery of active agents |
| 06/10/2011 | CA2688105A1 Virally induced biofilm-like structure and uses thereof |
| 06/09/2011 | WO2011068863A1 Combination therapy for treating cancer and diagnostic assays for use therein |
| 06/09/2011 | WO2011067212A1 Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
| 06/09/2011 | US20110136851 Sucralose Formulations To Mask Unpleasant Tastes |
| 06/09/2011 | US20110136826 Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis |
| 06/09/2011 | US20110136739 Use of S1P Receptor Agonists in Heart Diseases |
| 06/09/2011 | US20110135731 Abuse-resistant opioid dosage form |
| 06/09/2011 | US20110135722 Pharmaceutical formulation comprising a proton pump inhibitor and antacids |
| 06/09/2011 | US20110135684 Use of L-alpha-lysophosphatidylcholine to obtain the differentiation of monocytes in mature dendritic cells in vitro |
| 06/09/2011 | US20110135660 Prevention and treatment of synucleinopathic disease |
| 06/09/2011 | US20110135595 Neuregulin based methods and compositions for treating cardiovascular disease |
| 06/09/2011 | CA2781487A1 Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
| 06/09/2011 | CA2778675A1 Combination therapy for treating cancer and diagnostic assays for use therein |
| 06/08/2011 | EP2330219A2 Method for drug discovery, disease treatment and diagnosis using metabolomics |
| 06/08/2011 | EP2330197A2 Antagonistic selective binding agents of osteoprotegerin binding protein |
| 06/08/2011 | EP2330194A2 Non-sequence complementary antiviral oligonucleotides |
| 06/08/2011 | EP2330129A2 Anti-TNF antibodies, compositions, methods and uses |
| 06/08/2011 | EP2330092A2 Medicament comprising steviol or isosteviol for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome |
| 06/08/2011 | EP2329862A1 Nitrate esters and their use for the treatment of muscle and muscle related diseases |
| 06/08/2011 | EP2329861A1 Pharmaceutical products and compositions comprising formoterol, budesonide and ipratropium |
| 06/08/2011 | EP2329850A2 System and methods for optimized drug delivery and progression of diseased and normal cells |
| 06/08/2011 | EP2329849A1 Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder |
| 06/08/2011 | EP2329848A1 Lixisenatide as add-on therapy to insulin glargine and metformin for treating type 2 diabetes |
| 06/08/2011 | EP2329847A2 Use of an antibody or an immunotoxin that selectively binds to CD123 to impair hematologic cancer progenitor cells |
| 06/08/2011 | EP2329839A1 Modification of feeding behavior by GLP-1 and PYY |
| 06/08/2011 | EP2328892A1 Oxotetrahydrofuran-2-yl-benzimidazole derivative |
| 06/08/2011 | EP2328889A1 Acetyl pyrrolidinyl indole derivative |
| 06/08/2011 | EP2328595A1 Methods for stimulating chondrogenesis utilizing a potassium channel inhibitor |
| 06/08/2011 | EP2328578A2 Noscapine and noscapine analogs and their use in treating infectious diseases by tubulin binding inhibition |
| 06/08/2011 | EP2328571A1 Amino alcohol derivatives for the treatment of demyelinating peripheral neuropathies |
| 06/08/2011 | EP2328565A1 An extended release pharmaceutical composition of entacapone or salts thereof |
| 06/08/2011 | EP2328555A2 Compositions for the treatment of neoplastic diseases |
| 06/08/2011 | EP2125021B1 Combination therapy of lower urinary tract disorders with 2 ligands and nsaids |
| 06/08/2011 | EP1937264B1 Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence |
| 06/08/2011 | EP1880001B1 Feline probiotic lactobacilli |
| 06/08/2011 | EP1771200B1 Physiologically-active composition based on collagen |
| 06/08/2011 | EP1531800B1 Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s) |
| 06/08/2011 | EP1485127B1 Administration of agents for the treatment of inflammation |
| 06/08/2011 | EP1479397B1 2,4,6-triamino-1,3,5-triazine derivative |
| 06/08/2011 | EP1434579B1 Imidazole derivatives as antiinflammatory agents |
| 06/08/2011 | EP1427427B1 Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect |
| 06/08/2011 | EP1296665B1 Analgesic and anti-inflammatory compositions containing celecoxib and ibuprofen |
| 06/08/2011 | CN1966080B Neural stem cell injection for treating senile dementia and Parkinson's disease |
| 06/08/2011 | CN1893979B Remedy for angitis |
| 06/08/2011 | CN102089007A Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of RAS/RAF/MEK pathway |
| 06/08/2011 | CN102089006A Compositions and methods for producing vascular occlusion using a solid-phase platelet binding agent |
| 06/08/2011 | CN102089001A Immunity-inducing agent and method for detection of cancer |
| 06/08/2011 | CN102088969A Combination of spacitabine (CNDAC) and DNA methyltransferase inhibitors such as decitabine and procaine |
| 06/08/2011 | CN102088967A Therapy regimen for treating acne related diseases |
| 06/08/2011 | CN102085373A Combinations comprising antimuscarinic agents and PDE4 inhibitors |
| 06/08/2011 | CN102085372A Application of Notch pathway inhibitor in treatment of tumors caused by activation of mTOR |
| 06/08/2011 | CN102085214A Low-molecular citrus pectin capable of being combined with clinical common chemotherapeutic drug for controlling cancer and cancer metastasis and diffusion |